509 related articles for article (PubMed ID: 24424304)
1. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
3. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
5. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
[TBL] [Abstract][Full Text] [Related]
8. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
9. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.
Das Thakur M; Stuart DD
Clin Cancer Res; 2014 Mar; 20(5):1074-80. PubMed ID: 24352648
[TBL] [Abstract][Full Text] [Related]
13. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
14. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
Whittaker S; Kirk R; Hayward R; Zambon A; Viros A; Cantarino N; Affolter A; Nourry A; Niculescu-Duvaz D; Springer C; Marais R
Sci Transl Med; 2010 Jun; 2(35):35ra41. PubMed ID: 20538618
[TBL] [Abstract][Full Text] [Related]
15. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
16. Mutant B-Raf Kinase Inhibitors as Anticancer Agents.
Asati V; Bharti SK; Mahapatra DK
Anticancer Agents Med Chem; 2016; 16(12):1558-1575. PubMed ID: 27264268
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
[TBL] [Abstract][Full Text] [Related]
18. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
20. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]